Trial · NCT03530800
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors
NCT03530800, Phase 2, Phase 3, Completed, University of Chicago; results first posted 2022-06-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors. Trials, record NCT03530800. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03530800
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors
- NCT number
- NCT03530800
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 50 participants, actual
- Lead sponsor
- University of Chicago
- Conditions
- Trichotillomania, Skin-Picking
- Interventions
- Dronabinol, Placebo
- First posted
- 2018-05-21
- Last updated
- 2022-06-02
- Results first posted
- 2022-06-02
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | NIMH Trichotillomania Symptom Severity Scale (NIMH-TSS) | Assessed every two weeks up to 10 weeks, baseline data reported | The entire study lasts 10 weeks. Every two weeks subjects will take the NIMH-TSS. The change in scores from baseline to after 10 weeks will be assessed. The scale itself assesses severity of trichotillomania symptoms. The NIMH-TSS score ranges from 0 to 20, with 0 being no symptoms and 20 being the most severe. |
| Primary | Skin Picking Symptom Assessment Scale (SP-SAS) | Assessed every two weeks up to 10 weeks, baseline reported | The entire study lasts 10 weeks. Every two weeks subjects will take the SP-SAS. The change in scores from baseline to after 10 weeks will be assessed. The scale itself assesses severity of skin-picking symptoms. The SP-SAS score ranges from 0 to 48, with 0 being no symptoms and 48 being the most severe. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | NIMH Trichotillomania Symptom Severity Scale (NIMH-TSS) | Assessed every two weeks up to 10 weeks, baseline data reported | Data provided for subjects that reported data | score on a scale | MEAN |
| PRIMARY | Skin Picking Symptom Assessment Scale (SP-SAS) | Assessed every two weeks up to 10 weeks, baseline reported | Data provided for subjects that reported data | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| NIMH Trichotillomania Symptom Severity Scale (NIMH-TSS) | Dronabinol | 12.38 | Standard Deviation 3.15 | score on a scale | |
| NIMH Trichotillomania Symptom Severity Scale (NIMH-TSS) | Placebo | 10.63 | Standard Deviation 3.42 | score on a scale | |
| Skin Picking Symptom Assessment Scale (SP-SAS) | Dronabinol | 24.44 | Standard Deviation 9.46 | score on a scale | |
| Skin Picking Symptom Assessment Scale (SP-SAS) | Placebo | 28.5 | Standard Deviation 4.23 | score on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dronabinol | 25 | |
| Overall Study | STARTED | Placebo | 25 | |
| Overall Study | COMPLETED | Dronabinol | 14 | |
| Overall Study | COMPLETED | Placebo | 16 | |
| Overall Study | NOT COMPLETED | Dronabinol | 11 | |
| Overall Study | NOT COMPLETED | Placebo | 9 |
Source ClinicalTrials.gov
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Light headed/dizzy | General disorders | Dronabinol | 5 | 25 | 5 |
| other | Light headed/dizzy | General disorders | Placebo | 1 | 1 | 1 |
| other | High (easy laughing, elation, heightened awareness) | General disorders | Dronabinol | 4 | 25 | 4 |
| other | High (easy laughing, elation, heightened awareness) | General disorders | Placebo | 0 | 25 | 0 |
| other | Cognitive blunting, attentional problems | Psychiatric disorders | Dronabinol | 4 | 25 | 4 |
| other | Cognitive blunting, attentional problems | Psychiatric disorders | Placebo | 2 | 25 | 2 |
| other | Sedation | General disorders | Dronabinol | 5 | 25 | 5 |
| other | Sedation | General disorders | Placebo | 3 | 25 | 3 |
| other | Dry mouth | General disorders | Dronabinol | 4 | 25 | 4 |
| other | Dry mouth | General disorders | Placebo | 2 | 25 | 2 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dronabinol | 0 | 25 |
| Total, all-cause mortality | Placebo | 0 | 25 |
| Total, other adverse events | Dronabinol | 16 | 25 |
| Total, other adverse events | Placebo | 7 | 25 |
| Total, serious adverse events | Dronabinol | 0 | 25 |
| Total, serious adverse events | Placebo | 0 | 25 |
Source ClinicalTrials.gov
Papers21
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Dronabinol vs Placebo: deaths from any cause | Trial comparisons |
| Dronabinol vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03530800
GET https://conductscience.org/api/trials/v1/NCT03530800/papers?page=2